Home > Publications Database > Health-related quality of life in patients with paediatric inflammatory bowel disease: IMPACT-III validation in Germany. > print

001     281525
005     20251030102704.0
024 7 _ |a 10.1186/s12955-025-02437-0
|2 doi
024 7 _ |a pmid:41039592
|2 pmid
024 7 _ |a pmc:PMC12492618
|2 pmc
037 _ _ |a DZNE-2025-01143
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Boerkoel, Aletta
|b 0
245 _ _ |a Health-related quality of life in patients with paediatric inflammatory bowel disease: IMPACT-III validation in Germany.
260 _ _ |a London
|c 2025
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1761740269_30627
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Health related quality of life (HRQoL) in paediatric patients with inflammatory bowel disease (IBD) is typically measured using the patient reported outcome measure IMPACT-III. This measure has not yet been validated for German patients using the new 4-domain structure. As Germany has a comparatively high prevalence of paediatric IBD and as the IMPACT-III is the main HRQoL outcome measure in use, a validation in the German population is overdue.To validate the main patient reported outcome measure of health-related quality of life (HRQoL) in paediatric patients with inflammatory bowel disease (IBD) IMPACT-III in a German patient sample.Clinical and HRQoL data was gathered in the CEDATA-GPGE registry. To determine the psychometric performance of the IMPACT-III in a German sample, distribution properties, reliability (Cronbach's alpha) and validity (correlations with clinical values; known-groups validity by age, sex, and self-rated health) were calculated. In addition, a confirmatory factor analysis was performed to determine the appropriateness of the factor structure.The IMPACT-III was filled out by 221 patients (Female 46%; Mage=14.05; Morbus Crohn n = 126; Ulcerative Colitis n = 79; unclassified IBD n = 18). The total score ranged from 19.29 to 95.00, without the occurrence of ceiling or floor effects. Internal consistency using Cronbach's alpha was excellent (α = 0.91) for the total scale. The total score correlated strongly with the subscales of wellbeing (r = 0.90) and social functioning (r = 0.80). Concerning validity, the subscale of wellbeing correlated with self-reported health and clinical assessments. Younger patients (< 14) reported a significantly better HRQoL than older patients (14-17). The 4-domain structure of IMPACT-III could not be confirmed through factor analysis.The German version of the IMPACT-III is a valid and reliable instrument to measure HRQoL in paediatric patients with IBD. The subscales of well-being and social functioning explain most of the total score. To interpret the subdomains of the IMPACT-III further research in a longitudinal design needs to be done, especially with age-related phrasing of the items.German Clinical Trials Register DRKS00015505. Registered on 22.01.2019 Inclusion of patients 01.03.2019; https://drks.de/search/en/trial/DRKS00015505 .
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Health related quality of life
|2 Other
650 _ 7 |a Paediatric inflammatory bowel diseases
|2 Other
650 _ 7 |a Patient reported outcomes
|2 Other
650 _ 7 |a Psychometric testing
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Quality of Life: psychology
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Germany
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Psychometrics
|2 MeSH
650 _ 2 |a Child
|2 MeSH
650 _ 2 |a Inflammatory Bowel Diseases: psychology
|2 MeSH
650 _ 2 |a Patient Reported Outcome Measures
|2 MeSH
650 _ 2 |a Reproducibility of Results
|2 MeSH
650 _ 2 |a Surveys and Questionnaires: standards
|2 MeSH
700 1 _ |a Buchholz, Maresa
|0 P:(DE-2719)9002138
|b 1
|u dzne
700 1 _ |a Tischler, Luisa
|b 2
700 1 _ |a Weber, Niklas
|0 P:(DE-2719)9001915
|b 3
|u dzne
700 1 _ |a Hoffmann, Wolfgang
|0 P:(DE-2719)2000040
|b 4
|u dzne
700 1 _ |a de Laffolie, Jan
|b 5
700 1 _ |a Berg, Neeltje van den
|b 6
700 1 _ |a Group, CEDATA Study
|b 7
|e Collaboration Author
773 _ _ |a 10.1186/s12955-025-02437-0
|g Vol. 23, no. 1, p. 94
|0 PERI:(DE-600)2098765-1
|n 1
|p 94
|t Health and quality of life outcomes
|v 23
|y 2025
|x 1477-7525
856 4 _ |u https://pub.dzne.de/record/281525/files/DZNE-2025-01143%20SUP.xlsx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281525/files/DZNE-2025-01143.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281525/files/DZNE-2025-01143.pdf?subformat=pdfa
856 4 _ |u https://pub.dzne.de/record/281525/files/DZNE-2025-01143%20SUP.csv
856 4 _ |u https://pub.dzne.de/record/281525/files/DZNE-2025-01143%20SUP.ods
856 4 _ |u https://pub.dzne.de/record/281525/files/DZNE-2025-01143%20SUP.xls
909 C O |o oai:pub.dzne.de:281525
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002138
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001915
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2000040
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0130
|2 StatID
|b Social Sciences Citation Index
|d 2024-12-10
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-10
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b HEALTH QUAL LIFE OUT : 2022
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1180
|2 StatID
|b Current Contents - Social and Behavioral Sciences
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:39:47Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:39:47Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-10
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-10
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-10
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-10
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-10
920 1 _ |0 I:(DE-2719)1510800
|k AG Thyrian
|l Interventional Health Care Research (IHCR)
|x 0
920 1 _ |0 I:(DE-2719)5000067
|k AG Michalowsky
|l Patient-Reported Outcomes and Health Economics Research
|x 1
920 1 _ |0 I:(DE-2719)1510600
|k AG Hoffmann
|l Translational Health Care Research
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1510800
980 _ _ |a I:(DE-2719)5000067
980 _ _ |a I:(DE-2719)1510600
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21